Hanefeld, M.* ; Engelmann, K.* ; Appelt, D.* ; Sandner, D.* ; Weigmann, I.* ; Ganz, X.* ; Pistrosch, F.* ; Koehler, C.M.* ; Gasparic, A.* ; Birkenfeld, A.L.
     
    
        
Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetes.
    
    
        
    
    
        
        PLoS ONE 12:e0184234 (2017)
    
    
    
      
      
	
	    Increased levels of systemic vascular endothelial growth factors (VEGFs) in patients with diabetes are associated with increased risk of microvessel disease. On the other hand, low VEGF levels after intravitreal antibody application may be associated with acute cardiovascular complications and treatment failure. Individual levels of systemic VEGF vary in a wide range depending on analytical methods and quality of diabetes control. So far only limited information exists on intraindividual fluctuations over longer periods and circadian rhythms. We analysed the intraindividual variance of VEGF-A, VEGF-C and placental growth factor (PLGF) in CTAD (citrate-theophylline-adenine-dipyridamol) plasma as well as VEGF-A in serum over a period of 6 months in patients with stable controlled type 2 diabetes (10 M, 10 F) and age and sex matched subjects with normal glucose tolerance (NGT). Furthermore, circadian levels of VEGFs were controlled hourly from 7: 30 a. m. to 7: 30 p. m. under standardized metabolic ward conditions. In addition, the relationship to metabolic, hormonal and inflammatory biomarkers was analyzed. VEGF-A, VEGF-C and PLGF remained stable in plasma and VEGF-A in serum over 6 months in both groups. No circadian change was observed in VEGF-A serum and plasma concentrations. A minor decrease of VEGF-C plasma levels was evident after 5 p. m. in both groups and a significant peak of PLGF concentrations occurred after lunch, which was more pronounced in T2DM. In multivariate analysis, only serum VEGF-A correlated to diabetes duration, whereas VEGF-C only correlated to HbA1c and fasting blood glucose. We did not observe significant intraindividual variances for VEGF-A in serum and VEGF-A, VEGF-C and PLGF in CTAD plasma over a period of 6 months. Taken together, a single morning measurement of systemic VEGF levels after 7: 30 am appears to be a reliable parameter for the individual risk associated with abnormal VEGF concentrations in blood.
	
	
	    
	
       
      
	
	    
		Impact Factor
		Scopus SNIP
		Web of Science
Times Cited
		Scopus
Cited By
		Altmetric
		
	     
	    
	 
       
      
     
    
        Publication type
        Article: Journal article
    
 
    
        Document type
        Scientific Article
    
 
    
        Thesis type
        
    
 
    
        Editors
        
    
    
        Keywords
        Macular Degeneration; Intravitreal Injection; Plasma-levels; Vegf Levels; Glycemic Control; Serum; Ranibizumab; Bevacizumab; Platelets; Therapy
    
 
    
        Keywords plus
        
    
 
    
    
        Language
        english
    
 
    
        Publication Year
        2017
    
 
    
        Prepublished in Year
        
    
 
    
        HGF-reported in Year
        2017
    
 
    
    
        ISSN (print) / ISBN
        1932-6203
    
 
    
        e-ISSN
        
    
 
    
        ISBN
        
    
    
        Book Volume Title
        
    
 
    
        Conference Title
        
    
 
	
        Conference Date
        
    
     
	
        Conference Location
        
    
 
	
        Proceedings Title
        
    
 
     
	
    
        Quellenangaben
        
	    Volume: 12,  
	    Issue: 10,  
	    Pages: ,  
	    Article Number: e0184234 
	    Supplement: ,  
	
    
 
    
        
            Series
            
        
 
        
            Publisher
            Public Library of Science (PLoS)
        
 
        
            Publishing Place
            Lawrence, Kan.
        
 
	
        
            Day of Oral Examination
            0000-00-00
        
 
        
            Advisor
            
        
 
        
            Referee
            
        
 
        
            Examiner
            
        
 
        
            Topic
            
        
 
	
        
            University
            
        
 
        
            University place
            
        
 
        
            Faculty
            
        
 
    
        
            Publication date
            0000-00-00
        
 
         
        
            Application date
            0000-00-00
        
 
        
            Patent owner
            
        
 
        
            Further owners
            
        
 
        
            Application country
            
        
 
        
            Patent priority
            
        
 
    
        Reviewing status
        Peer reviewed
    
 
    
        Institute(s)
        Institute of Pancreatic Islet Research (IPI)
    
 
    
        POF-Topic(s)
        90000 - German Center for Diabetes Research
    
 
    
        Research field(s)
        Helmholtz Diabetes Center
    
 
    
        PSP Element(s)
        G-502600-012
    
 
    
        Grants
        
    
 
    
        Copyright
        
    
 	
    
    
    
    
    
        Erfassungsdatum
        2017-11-13